Sugi Predict
/ Targets
/ NTRK1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to NTRK1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors |
PHASE2 | RECRUITING |
| A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors |
PHASE2 | COMPLETED |
| A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities |
PHASE1/PHASE2 | RECRUITING |
| A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer |
PHASE2 | WITHDRAWN |
| Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors |
PHASE2 | RECRUITING |
| A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients |
PHASE2 | RECRUITING |
| A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations |
PHASE1/PHASE2 | RECRUITING |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Study of FCN-098 in Patients With Advanced Solid Tumor |
PHASE1 | UNKNOWN |
| A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer |
PHASE1 | COMPLETED |
| A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b |
PHASE1 | COMPLETED |
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers |
PHASE1 | ENROLLING_BY_INVITATION |
| N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma |
PHASE1 | COMPLETED |
| AZD7451 for Recurrent Gliomas |
PHASE1 | COMPLETED |
| A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer |
PHASE1 | COMPLETED |
| NTRK 1,2,3 Rearrangements in Patients With Solid Tumors |
nan | ACTIVE_NOT_RECRUITING |
| A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib |
nan | COMPLETED |
| A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study |
nan | COMPLETED |
| Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion |
nan | COMPLETED |
| Association of Urine BDNF and NGF With Lower Urinary System Parameters |
nan | RECRUITING |
| Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma |
nan | COMPLETED |
| Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. |
nan | UNKNOWN |
| Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion |
nan | APPROVED_FOR_MARKETING |
| Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion |
nan | NO_LONGER_AVAILABLE |
| RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions. |
nan | ACTIVE_NOT_RECRUITING |
| Spanish Study for Molecular Characterization of Thyroid Carcinoma |
nan | ACTIVE_NOT_RECRUITING |
| Studying Gene Expression in Samples From Younger Patients With Neuroblastoma |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a NTRK1 binder may also engage these)